



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket
44921-5058-01-USApplication No.
09/084,471Applicants: Patricia Murphy *et al.*

Page 1 of 3

Filing Date: May 22, 1998

Group: 1655

U.S. PATENT DOCUMENTS

Initial		Serial No.	Date	Name	Class	SubClass	Filing Date
CM	aa	4,683,202	07/28/87	Mullis	435	91	10/25/85
	ab	5,545,531	08/13/96	Rava <i>et al.</i>	435	6	06/7/95
	ac	5,561,058	10/01/96	Gelfand <i>et al.</i>	435	912	05/24/95
	ad	5,582,989	12/10/96	Caskey <i>et al.</i>	435	6	09/30/94
	ae	5,589,330	12/31/96	Shuber	435	5	07/28/94
	af	5,624,803	04/29/97	Noonberg <i>et al.</i>	435	6	10/13/94
	ag	5,650,316	07/22/97	Aggarwal <i>et al.</i>	435	375	06/06/94
	ah	5,654,155	08/05/97	Murphy <i>et al.</i>	435	6	02/12/96
	ai	5,693,473	12/02/97	Shattuck-Eidens <i>et al.</i>	435	6	06/07/95
	aj	5,709,999	01/20/98	Shattuck-Eidens <i>et al.</i>	435	6	06/07/95
	ak	5,710,001	01/20/98	Skolnich <i>et al.</i>	435	6	06/07/95
	al	5,726,019	03/10/98	Sidransky	435	6	12/28/95
	am	5,747,282	05/05/98	Skolnick <i>et al.</i>	435	69.1	06/07/95
	an	5,753,441	05/19/98	Skolnick <i>et al.</i>	435	6	01/05/96
	ao	5,756,294	05/26/98	White <i>et al.</i>	435	6	09/25/95
	ap	5,858,669	01/12/99	Levine	435	6	09/13/96
	aq	5,891,857	04/06/99	Holt <i>et al.</i>	514	44	02/20/96
	ar	5,912,127	06/15/99	Narod <i>et al.</i>	435	6	02/28/97
	as	5,948,643	09/07/99	Rubinfeld <i>et al.</i>	435	69.1	08/13/97
CM	at	5,965,377	10/12/99	Adams <i>et al.</i>	435	7.23	03/20/98

Examiner

Date Considered

Examiner:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket
44921-5058-01-USApplication No.
09/084,471Applicants: Patricia Murphy *et al.*

Page 2 of 3

Filing Date: May 22, 1998

Group: 1655

U.S. PATENT DOCUMENTS

Initial		Serial No.	Date	Name	Class	SubClass	Filing Date
CM	au	6,033,857	03/07/00	Tavtigian <i>et al.</i>	435	6	03/20/98
	av	6,045,997	04/04/00	Futreal <i>et al.</i>	435	6	11/25/96
	aw	6,083,698	07/04/00	Olson <i>et al.</i>	435	6	12/11/97
	ax	6,051,379	08/18/00	Lescallett <i>et al.</i>	435	6	12/02/97
	ay	6,124,104	09/26/00	Tavtigian <i>et al.</i>	435	7.2	03/20/98
CM	az	6,130,322	10/10/00	Murphy <i>et al.</i>	536	23.1	05/06/98

FOREIGN PATENT DOCUMENTS

Initial		Document No.	Date	Country	Class	SubClass	Translation
CM	ba	GB 2307477A	05/28/97	GB			
	bb	EP 0699754A1	06/03/96	EP			
	bc	EP 0705902A1	10/04/96	EP			
	bd	EP 0705903A1	10/04/96	EP			
	be	WO 9304200	03/04/93	PCT			
	bf	WO 9519369	07/20/95	PCT			
	bg	WO 9722689	06/26/97	PCT			
	bh	WO 9730108	08/21/97	PCT			
	bi	WO 9815654	04/16/98	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

CM	bj	Hacia <i>et al.</i> , Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis, Nat. Genet. 14:441-447 (1996)
----	----	--

Examiner

C. M. Myers

Date Considered

9-22-04

Examiner:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket
44921-5058-01-USApplication No.
09/084,471Applicants: Patricia Murphy *et al.*

Page 3 of 3

Filing Date: May 22, 1998

Group: 1655

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C-7

bk

Bignell *et al.*, The BRC repeats are conserved in mammalian BRCA2 proteins, Hum. Mol. Genet. 6:53-58 (1997)

C-1

bl

Neuhausen *et al.*, Recurrent BRCA2 6174delT Mutations in Ashkenazi Jewish Women Affected by Breast Cancer, Nat. Genet. 13:126-128 (1996)

Examiner

Carla Meyer

Date Considered

9-22-04

Examiner:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.